These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 19596191)

  • 1. Targeted therapies in the treatment of advanced/metastatic NSCLC.
    Pallis AG; Serfass L; Dziadziusko R; van Meerbeeck JP; Fennell D; Lacombe D; Welch J; Gridelli C
    Eur J Cancer; 2009 Sep; 45(14):2473-87. PubMed ID: 19596191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted therapy in advanced non-small-cell lung cancer.
    Gettinger S
    Semin Respir Crit Care Med; 2008 Jun; 29(3):291-301. PubMed ID: 18506667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors.
    Cabebe E; Wakelee H
    Curr Treat Options Oncol; 2007 Feb; 8(1):15-27. PubMed ID: 17634832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Lung cancer].
    Fischer B; Buhl R
    Med Klin (Munich); 2008 May; 103(5):311-20. PubMed ID: 18484217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging data with antiangiogenic therapies in early and advanced non-small-cell lung cancer.
    Horn L; Sandler AB
    Clin Lung Cancer; 2009 Mar; 10 Suppl 1(Suppl 1):S7-16. PubMed ID: 19362948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage.
    Petrelli A; Giordano S
    Curr Med Chem; 2008; 15(5):422-32. PubMed ID: 18288997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New insights in drug development for the non-small cell lung cancer therapy.
    Gridelli C; Rossi A; Maione P; Ferrara C; Del Gaizo F; Guerriero C; Nicolella D; Palazzolo G; Falanga M; Colantuoni G
    Front Biosci; 2008 May; 13():5108-19. PubMed ID: 18508573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiogenesis Inhibitors in NSCLC.
    Manzo A; Montanino A; Carillio G; Costanzo R; Sandomenico C; Normanno N; Piccirillo MC; Daniele G; Perrone F; Rocco G; Morabito A
    Int J Mol Sci; 2017 Sep; 18(10):. PubMed ID: 28934120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer.
    Gridelli C; Maione P; Del Gaizo F; Colantuoni G; Guerriero C; Ferrara C; Nicolella D; Comunale D; De Vita A; Rossi A
    Oncologist; 2007 Feb; 12(2):191-200. PubMed ID: 17296815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NSCLC drug targets acquire new visibility.
    Friedrich MJ
    J Natl Cancer Inst; 2011 Mar; 103(5):366-7. PubMed ID: 21357596
    [No Abstract]   [Full Text] [Related]  

  • 11. [Tumor vasculature as a therapeutic target in non-small cell lung cancer].
    Döme B; Magyar M
    Magy Onkol; 2008 Sep; 52(3):247-59. PubMed ID: 18845495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of angiogenesis inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis.
    Hong S; Tan M; Wang S; Luo S; Chen Y; Zhang L
    J Cancer Res Clin Oncol; 2015 May; 141(5):909-21. PubMed ID: 25373315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [New therapeutic options for advanced thyroid cancer].
    Willhauck MJ; Schott M; Kreissl MC; Fassnacht M; Spitzweg C
    Dtsch Med Wochenschr; 2011 Jun; 136(22):1165-8. PubMed ID: 21611920
    [No Abstract]   [Full Text] [Related]  

  • 14. Targeted therapy for metastatic renal cell carcinoma.
    Motzer RJ; Bukowski RM
    J Clin Oncol; 2006 Dec; 24(35):5601-8. PubMed ID: 17158546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of the incorporation of tyrosine kinase inhibitor agents on the treatment of patients with a diagnosis of advanced renal cell carcinoma: study based on experience at the Hospital Universitario Central de Asturias.
    Muriel C; Esteban E; Corral N; Fonseca PJ; Luque M; Berros JP; Fernández Y; Blay P; Fra J; Villanueva N; Sanmamed M; Pardo P; Izquierdo M; Vieitez JM; Estrada E; Lacave ÁJ
    Clin Transl Oncol; 2010 Aug; 12(8):562-7. PubMed ID: 20709657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toxicities of antiangiogenic therapy in non-small-cell lung cancer.
    Herbst RS
    Clin Lung Cancer; 2006 Dec; 8 Suppl 1():S23-30. PubMed ID: 17239287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent advances in the systemic treatment of metastatic papillary renal cancer.
    Chowdhury S; Choueiri TK
    Expert Rev Anticancer Ther; 2009 Mar; 9(3):373-9. PubMed ID: 19275514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
    Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [New anti-cancer agents--from cytotoxic systemic chemotherapy to target-based agents].
    Yokoba M; Yanase N; Masuda N
    Gan To Kagaku Ryoho; 2005 Jun; 32(6):783-8. PubMed ID: 15984516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted therapy for the treatment of non-small cell lung cancer: focus on inhibition of epidermal growth factor receptor.
    Harichand-Herdt S; Ramalingam SS
    Semin Thorac Cardiovasc Surg; 2008; 20(3):217-23. PubMed ID: 19038731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.